Found: 4
Select item for more details and to access through your institution.
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
- Published in:
- Breast Cancer (13406868), 2024, v. 31, n. 5, p. 886, doi. 10.1007/s12282-024-01603-4
- By:
- Publication type:
- Article
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
- Published in:
- Oncologist, 2023, v. 28, n. 10, p. 845, doi. 10.1093/oncolo/oyad139
- By:
- Publication type:
- Article
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1191, doi. 10.1007/s00280-013-2113-1
- By:
- Publication type:
- Article
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article